Clinical Efficacy of Modified Huangqin Xiebai Powder Plus Maxing Shigan Decoction for Phlegm-Heat Obstructing the Lung Syndrome with Pediatric Mycoplasma Pneumoniae

Objective: To evaluate the clinical efficacy of modified Huangqin Xiebai powder combined with Maxing Shigan decoction in treating Phlegm-Heat Obstructing the Lung Syndrome with Mycoplasma pneumoniae pneumonia (MPP) in children. Methods: Sixty pediatric patients diagnosed with Phlegm-Heat Obstructing the Lung Syndrome with MPP, aged between 0 and 14 years and treated at our institution from October 2023 to January 2024, were recruited. These participants were randomly allocated into the experimental and control groups (n=30). The control group received standard medical therapy, whereas the experimental group received standard therapy supplemented with modified Huangqin Xiebai powder and Maxing Shigan decoction. Both groups underwent 7 consecutive days of treatment. Clinical efficacy, traditional Chinese medicine (TCM) syndrome scores, laboratory indices, and adverse event rates were evaluated and compared between groups. Results: The experimental group exhibited a significantly superior clinical response rate (96.66%) relative to the control group (χ²=5.129, P=0.023). Following treatment, white blood cell (WBC) counts decreased in both groups, though without significant differences (P>0.05); however, the extent of reduction was more pronounced in the experimental group. C-reactive protein (CRP) levels declined substantially in both groups, with the experimental group demonstrating notably greater improvement (P